亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

180-day efficacy of nirsevimab against hospitalisation for respiratory syncytial virus lower respiratory tract infections in infants (HARMONIE): a randomised, controlled, phase 3b trial

医学 呼吸道感染 呼吸系统 下呼吸道感染 呼吸道 随机对照试验 内科学
作者
Alasdair Peter Stuart Munro,Simon B. Drysdale,Katrina Cathie,Florence Flamein,Markus Knuf,Andrea M. Collins,Helen C. Hill,Friedrich Kaiser,Robert Cohen,Didier Pinquier,Natalya Vassilouthis,Mariana Carreno,Catherine Moreau,Pierre Bourron,Lydie Marcelon,Karine Mari,Michelle Roberts,Pierre Tissières,Simon Royal,Saul N. Faust
出处
期刊:The Lancet Child & Adolescent Health [Elsevier BV]
卷期号:9 (6): 404-412 被引量:74
标识
DOI:10.1016/s2352-4642(25)00102-6
摘要

BACKGROUND: Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infection and hospitalisations in infants worldwide. The primary analyses of HARMONIE showed that nirsevimab reduced infant hospitalisations due to RSV-associated lower respiratory tract infection through the RSV season. This analysis aims to evaluate nirsevimab's efficacy at 180 days after dosing, a period exceeding the typical 5-month RSV season. METHODS: HARMONIE is an ongoing, open-label, parallel arm, randomised, controlled, phase 3b study conducted in France, Germany, and the UK. Infants aged 12 months or younger, born at a gestational age of at least 29 weeks, were randomly assigned (1:1) to receive either a single intramuscular dose of nirsevimab (50 mg for children <5 kg or 100 mg for children ≥5 kg) or standard care (without RSV prophylaxis) before or during their first RSV season. Randomisation was electronically done, stratified by country and age-group. The primary efficacy endpoint for this analysis was the incidence of hospitalisations due to RSV-associated lower respiratory tract infection up to 180 days after nirsevimab administration or randomisation in all randomised participants. Safety up to 365 days following nirsevimab administration was also assessed. This trial is ongoing and registered with ClinicalTrials.gov, number NCT05437510. FINDINGS: Between Aug 8, 2022, and Feb 28, 2023, 8057 infants were randomly assigned to either the nirsevimab group (n=4038) or the standard care group (n=4019). The median age at randomisation was 4·00 months (IQR 1·0-7·0; range 0·0-12·0, and 4195 (52·1%) were male and 3862 (47·9%) were female. Up to 180 days, 12 (0·3%) of 4038 infants in the nirsevimab group and 68 (1·7%) of 4019 infants in the standard care group had been hospitalised for RSV-associated lower respiratory tract infection, corresponding to a nirsevimab efficacy of 82·7% (95% CI 67·8-91·5; p<0·0001). Most participants experienced grade 1 (2759 [68·7%] of 4016 in the nirsevimab group; 2696 [67·1%] of 4018 in the standard care group) or grade 2 (1447 [36·0%] of 4016 in the nirsevimab group; 1436 [35·7%] of 4018 in the standard care group) treatment-emergent adverse events, and no apparent safety concerns were raised up to 365 days after dosing. INTERPRETATION: Nirsevimab offers consistent and sustained protection against hospitalisation due to RSV-associated lower respiratory tract infection for at least 6 months. This finding provides global health systems greater flexibility when implementing nirsevimab, providing substantial benefit in the ongoing effort to reduce the burden of infant RSV and the potential wider public health value. FUNDING: Sanofi and AstraZeneca.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
5秒前
Ccccn完成签到,获得积分10
10秒前
Voiceless发布了新的文献求助10
13秒前
14秒前
满意的平凡完成签到,获得积分10
19秒前
伶俐的秀发完成签到,获得积分10
20秒前
ChenYQ完成签到,获得积分10
46秒前
苹果完成签到 ,获得积分10
53秒前
殷勤的半凡完成签到,获得积分10
1分钟前
耍酷的手套完成签到,获得积分10
1分钟前
1分钟前
1分钟前
充电宝的应助被爱学习的doge采纳,获得10
1分钟前
1分钟前
1分钟前
1分钟前
orixero的应助被爱学习的doge采纳,获得10
1分钟前
隐形曼青的应助被爱学习的doge采纳,获得10
1分钟前
在水一方的应助被爱学习的doge采纳,获得10
1分钟前
大模型的应助被爱学习的doge采纳,获得10
1分钟前
华仔的应助被爱学习的doge采纳,获得10
1分钟前
香蕉觅云的应助被爱学习的doge采纳,获得10
1分钟前
CodeCraft的应助被爱学习的doge采纳,获得10
1分钟前
SciGPT的应助被爱学习的doge采纳,获得10
1分钟前
隐形曼青的应助被爱学习的doge采纳,获得10
1分钟前
小二郎的应助被爱学习的doge采纳,获得10
1分钟前
852的应助被爱学习的doge采纳,获得10
1分钟前
1分钟前
田様的应助被爱学习的doge采纳,获得10
1分钟前
脑洞疼的应助被爱学习的doge采纳,获得10
1分钟前
bkagyin的应助被爱学习的doge采纳,获得10
1分钟前
顺利水桃完成签到,获得积分10
1分钟前
1分钟前
乐乐的应助被mengdewen采纳,获得10
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179924
求助须知:如何正确求助?哪些是违规求助? 9570159
关于积分的说明 21808379
捐赠科研通 7775767
什么是DOI,文献DOI怎么找? 3433193
关于科研通互助平台的介绍 2557347
邀请新用户注册赠送积分活动 2478918